Concepedia

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, Jaime Andrade‐Villanueva, Rosie Mngqibisa, Antonio Ocampo Hermida, Anders Thalme, Elena Belonosova, Faïza Ajana,

The Lancet HIV · 2021 · 135 citations · 15 references

DOI

Concepts

References

15

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases · 2019 · 750 citations · Full text

, , +15

Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease

Edward L. Murphy, Ann C. Collier, Leslie A. Kalish et al. · Annals of Internal Medicine · 2001 · 576 citations

, , +16

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 565 citations · Full text

, , +17

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 504 citations

, , +14

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

The HIV-CAUSAL Collaboration · AIDS · 2009 · 474 citations · Full text

, , +16